Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Fate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of twelve analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -42 cents to -28 cents per share.

• Revenue fell 71.8% to $1.91 million from a year ago; analysts expected $1.01 million.

• Fate Therapeutics Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $34.07 million.

• Fate Therapeutics Inc shares had fallen by 16.5% this quarter and lost 43.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00, about 81.3% above its last closing price of $0.94

This summary was machine generated from LSEG data August 12 at 08:35 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)